全球气喘垫片市场 - 2023-2030

概述

吸入器垫片、保温室和气喘垫片都是用于治疗气喘等呼吸系统疾病的医疗设备。它们旨在增强使用计量吸入器 (MDI) 将药物吸入肺部的方式。气喘间隔器对于确保患者完全服用处方药、降低副作用风险并提高治疗的整体疗效至关重要。

气喘、慢性阻塞性肺病 (COPD) 和支气管炎等呼吸系统疾病的盛行率不断上升，严重影响了气喘垫片市场。随着这些疾病变得更加普遍，对有效的呼吸系统药物输送方法（尤其是间隔器）的需求也随之增加。

现在，患者和医疗保健从业者更了解了使用气喘垫片的优点。垫片可提高药物输送至肺部的效率，最大限度地减少不良反应的可能性，并确保患者收到全部处方药物。

市场动态：驱动因素

哮喘盛行率不断增加

一种称为气喘的慢性呼吸系统疾病会导致肺部气道扩张和发炎。根据《柳叶刀》报道，2020年全球气喘统计数据显示，全球气喘患者人数正在上升，总数为3.39亿人。儘管气喘可以影响任何年龄层的人，但儿童比成人更容易患上这种疾病。儘管气喘的确切原因尚不清楚，但人们认为它是遗传和环境因素共同作用的结果。喘息、咳嗽、胸闷和气喘都是气喘的典型症状。

全球气喘网路撰写的《2022 年全球气喘报告》显示，气喘影响印度约 3,500 万人。报告称，诊断不足和治疗不足是印度对抗气喘的重大障碍。气喘也影响印度很大一部分儿童。控制气喘的干预措施必须从社区教育和初级保健水平所需药物和用品的优先顺序开始。

Zerostat VT Spacer 透明吸入器空间用于治疗气喘。该产品由优质材料製成，可长期使用。一种称为 Zerostat VT Spacer 透明吸入器空间的药物传输系统用于治疗气喘患者。它是一种采用雾化操作方法的吸入器。

缺乏意识和教育

对使用气喘间隔器的优点缺乏了解以及对正确使用间隔器的患者教育不足可能会阻碍市场扩张。许多患者和医疗保健专业人员可能尚未完全理解使用带有吸入器的垫片的好处。成本可能是使用气喘垫片的主要障碍。对于某些患者来说，这些设备可能会很昂贵，特别是如果他们没有保险或必须定期更换。有些患者可能喜欢雾化器和干粉吸入器 (DPI)，而不是带有储雾罐的 MDI。对气喘垫片的需求可能会根据个人喜好和使用特定设备的舒适程度而有所不同。

目录

第 1 章：方法与范围

• 研究方法论
• 报告的研究目的和范围

第 2 章：定义与概述

第 3 章：执行摘要

• 按产品类型分類的片段
• 按配销通路分類的片段
• 按地区分類的片段

第 4 章：动力学

• 影响因素
  • 司机
    • 哮喘盛行率不断增加
  • 限制
    • 缺乏意识和教育
  • 机会
  • 影响分析

第 5 章：产业分析

• 波特五力分析
• 供应链分析
• 定价分析
• 监管分析
• 俄乌战争影响分析
• SWOT分析
• 专利分析
• DMI 意见

第 6 章：COVID-19 分析

• COVID-19 分析
  • 新冠疫情爆发前的情景
  • 新冠疫情期间的情景
  • 新冠疫情后的情景
• COVID-19 期间的定价动态
• 供需谱
• 疫情期间政府与市场相关的倡议
• 製造商策略倡议
• 结论

第 7 章：按类型

• 空气舱
• 视室
• 体积
• 灵感酶

第 8 章：按配销通路

• 零售药房
• 医院药房
• 电子商务

第 9 章：按地区

• 北美洲
  • 我们
  • 加拿大
  • 墨西哥
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 欧洲其他地区
• 南美洲
  • 巴西
  • 阿根廷
  • 南美洲其他地区
• 亚太
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 亚太其他地区
• 中东和非洲

第 10 章：竞争格局

• 竞争场景
• 市场定位/份额分析
• 併购分析

第 11 章：公司简介

• Cipla Inc.
• 公司简介
• 产品组合和描述
• 财务概览
• 主要进展
• Koninklijke Philips NV
• Deposition Pulmonaire des Medicaments SAS
• Monaghan Medical Corporation
• Duomed
• Others

第 12 章：附录

Overview

Inhaler spacers, holding chambers, and asthma spacers are all medical devices used to treat respiratory disorders like asthma. They are made to enhance the way medication is inhaled into the lungs using metered-dose inhalers (MDIs). Asthma spacers are essential in ensuring that patients take their prescription medication in its entirety, lowering the risk of side effects, and enhancing the overall efficacy of treatment.

The market for asthma spacers has been significantly impacted by the rising prevalence of respiratory conditions such as asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. The need for efficient respiratory medicine delivery methods, particularly spacers, has increased as these illnesses become more widespread.

The advantages of employing asthma spacers are now better understood by patients and healthcare practitioners. Spacers increase the effectiveness of drug delivery to the lungs, minimizing the chance of adverse effects and guaranteeing that patients receive the entire quantity of their prescription medications.

Market Dynamics: Drivers

The Increasing Prevalence of Asthma

A chronic respiratory condition called asthma enlarges and inflames the lungs' airways. As per the Lancet, the asthma statistics worldwide for 2020 reported that the number of persons with asthma, a total of 339 million worldwide, is rising. Although asthma can afflict people of any age, children are more likely than adults to get the condition. Although the exact cause of asthma is unknown, it is thought to be a result of both hereditary and environmental factors. Wheezing, coughing, chest tightness, and shortness of breath are all typical signs of asthma.

The Global Asthma Report 2022, prepared by Global Asthma Network, shows that Asthma affects roughly 35 million people in India. According to the report, underdiagnosis and insufficient treatment are significant obstacles to the fight against asthma in India. Asthma also affects a significant portion of children in India. Interventions for controlling asthma must start with community education and the prioritization of required drugs and supplies at the primary healthcare level.

For the treatment of asthma, the Zerostat VT Spacer Transparent inhaler space is intended. This item is made of high-quality materials and will last you for a very long time. A drug delivery system called a Zerostat VT Spacer Transparent Inhaler Space is used to treat asthma patients. It is an inhaler that employs the aerosolization method of operation.

Lack of Awareness and Education

Lack of knowledge regarding the advantages of employing asthma spacers and insufficient patient education on their proper use can impede market expansion. The benefits of utilizing spacers with inhalers may not be fully understood by many patients and healthcare professionals. Cost can be a major obstacle to the use of asthma spacers. These devices might be costly for some patients, especially if they do not have insurance or if they have to replace them regularly. Nebulizers and dry powder inhalers (DPIs) may be preferred by some patients over MDIs with spacers. Demand for asthma spacers may vary depending on individual preferences and level of comfort using particular devices.

Segment Analysis

The global asthma spacers market is segmented based on type, distribution channel and region.

The aerochambers segment accounted for approximately 45.6% of the market share

Aerochambers are cutting-edge medical tools made to make it easier for people with asthma, COPD, or other respiratory disorders to breathe. Aerochambers are made up of a plastic tube that allows the drug spray to reach the patient, a mask that goes over the face or a mouthpiece on the front, and sometimes a plastic cover for the medication that is being administered that is attached to the back.

Depending on the age range, different models of aerochambers are available. Some manufacturers opt for a distinct model for each age range, such as one for children aged 1-6 and another for those above the age of 6, while others use a single aerochamber with a detachable aerochamber mask.

Biosynex Aerochambers come in infant, child, and adult sizes and are assured to be latex and bisphenol A-free. They are a crucial component of effective respiratory disease treatment. Biosynex aerochambers are designed for people of all ages who still find it difficult to take the medication with a metered dose inhaler.

Geographical Penetration

The Increasing Prevalence of Ashma and Advanced Healthcare Infrastructure

North America has been a dominant force in the global asthma spacers market. Where a person lives has a big impact on their asthma. People with asthma have a better chance of managing and treating their condition if they have access to inexpensive, quality healthcare, clean air, and stable economic conditions.

In April 2023, the American Lung Association estimates that 41.9 million Americans have ever had an asthma diagnosis. A persistent illness that affects the airways is asthma. Chest pain, coughing, and wheezing are some symptoms that can come and go. All ages are affected by asthma; however, it most often develops in children.

One sort of spacer that has a one-way valve at the mouthpiece is a valved holding chamber. More than just "space" between the mouth and the medication is provided by these devices. Additionally, it holds and traps medication, allowing patients to take a moment to exhale deeply. This makes it possible to inhale the complete pharmaceutical dose.

COVID-19 Impact Analysis

The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide. People with pre-existing respiratory illnesses, such as asthma, became more aware of their health as a result of the pandemic, which brought to light the significance of respiratory health. The demand for asthma spacers and other breathing devices may have increased as a result of the greater awareness.

Telemedicine and remote monitoring are two strategies that many healthcare providers have used to lower the danger of exposure to COVID-19. Through virtual consultations, patients with asthma and other respiratory disorders may have received advice on how to use and manage devices, thereby increasing the adoption of spacers.

By Product Type

• Aerochamber
• Optichamber
• Volumatic
• Inspirease

By Distribution Channel

• Retail Pharmacy
• Hospital Pharmacy
• E-Commerce

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Rest of Europe
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include: Cipla Inc, Koninklijke Philips N.V., Deposition Pulmonaire des Medicaments SAS, Monaghan Medical Corporation, Truedell Medical International, Duomed, PARI GmbH, Laboratoire ProtecSom and Haag-streit group among others.

Why Purchase the Report

• To visualize the global asthma spacers market segmentation based on type, distribution channel, and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of asthma spacers market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global asthma spacers market report would provide approximately 46 tables, 53 figures, and 186 Pages.

Target Audience 2023

• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

• 3.1. Snippet by Product Type
• 3.2. Snippet by Distribution Channel
• 3.3. Snippet by Region

4. Dynamics

• 4.1. Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. The Increasing Prevalence of Asthma
  • 4.1.2. Restraints
    • 4.1.2.1. Lack of Awareness and Education
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Porter's Five Force Analysis
• 5.2. Supply Chain Analysis
• 5.3. Pricing Analysis
• 5.4. Regulatory Analysis
• 5.5. Russia-Ukraine War Impact Analysis
• 5.6. SWOT Analysis
• 5.7. Patent Analysis
• 5.8. DMI Opinion

6. COVID-19 Analysis

• 6.1. Analysis of COVID-19
  • 6.1.1. Scenario Before COVID
  • 6.1.2. Scenario During COVID
  • 6.1.3. Scenario Post COVID
• 6.2. Pricing Dynamics Amid COVID-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 7.1.2. Market Attractiveness Index, By Type
• 7.2. Aerochamber*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 7.3. Optichamber
• 7.4. Volumatic
• 7.5. Inspirease

8. By Distribution Channel

• 8.1. Introduction
  • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 8.1.2. Market Attractiveness Index, By Distribution Channel
• 8.2. Retail Pharmacy*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
• 8.3. Hospital Pharmacy
• 8.4. E-Commerce

9. By Region

• 9.1. Introduction
  • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
  • 9.1.2. Market Attractiveness Index, By Region
• 9.2. North America
  • 9.2.1. Introduction
  • 9.2.2. Key Region-Specific Dynamics
  • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.2.5.1. U.S.
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. Europe
  • 9.3.1. Introduction
  • 9.3.2. Key Region-Specific Dynamics
  • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.3.5.1. Germany
    • 9.3.5.2. UK
    • 9.3.5.3. France
    • 9.3.5.4. Italy
    • 9.3.5.5. Spain
    • 9.3.5.6. Rest of Europe
• 9.4. South America
  • 9.4.1. Introduction
  • 9.4.2. Key Region-Specific Dynamics
  • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.4.5.1. Brazil
    • 9.4.5.2. Argentina
    • 9.4.5.3. Rest of South America
• 9.5. Asia-Pacific
  • 9.5.1. Introduction
  • 9.5.2. Key Region-Specific Dynamics
  • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
  • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    • 9.5.5.1. China
    • 9.5.5.2. India
    • 9.5.5.3. Japan
    • 9.5.5.4. Australia
    • 9.5.5.5. Rest of Asia-Pacific
• 9.6. Middle East and Africa
  • 9.6.1. Introduction
  • 9.6.2. Key Region-Specific Dynamics
  • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
  • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel

10. Competitive Landscape

• 10.1. Competitive Scenario
• 10.2. Market Positioning/Share Analysis
• 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

• 11.1. Cipla Inc.*
  • 11.1.1. Company Overview
  • 11.1.2. Product Portfolio and Description
  • 11.1.3. Financial Overview
  • 11.1.4. Key Developments
• 11.2. Koninklijke Philips N.V.
• 11.3. Deposition Pulmonaire des Medicaments SAS
• 11.4. Monaghan Medical Corporation
• 11.5. Duomed
• 11.6. Others

LIST NOT EXHAUSTIVE

12. Appendix

• 12.1. About Us and Services
• 12.2. Contact Us